TW515715B - Vaccine compositions having immunologically active QS21 - Google Patents
Vaccine compositions having immunologically active QS21 Download PDFInfo
- Publication number
- TW515715B TW515715B TW85104841A TW85104841A TW515715B TW 515715 B TW515715 B TW 515715B TW 85104841 A TW85104841 A TW 85104841A TW 85104841 A TW85104841 A TW 85104841A TW 515715 B TW515715 B TW 515715B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- item
- composition according
- vaccine composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 229960005486 vaccine Drugs 0.000 title claims abstract description 42
- 239000000427 antigen Substances 0.000 claims abstract description 38
- 102000036639 antigens Human genes 0.000 claims abstract description 38
- 108091007433 antigens Proteins 0.000 claims abstract description 38
- 229930182558 Sterol Natural products 0.000 claims abstract description 21
- 150000003432 sterols Chemical class 0.000 claims abstract description 21
- 235000003702 sterols Nutrition 0.000 claims abstract description 21
- 230000000890 antigenic effect Effects 0.000 claims abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 118
- 235000012000 cholesterol Nutrition 0.000 claims description 57
- 239000002502 liposome Substances 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229940037003 alum Drugs 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 241000589968 Borrelia Species 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- -1 alum Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 150000004712 monophosphates Chemical class 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 241000224016 Plasmodium Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000713800 Feline immunodeficiency virus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 27
- 238000009472 formulation Methods 0.000 description 22
- 206010018910 Haemolysis Diseases 0.000 description 15
- 230000008588 hemolysis Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000002079 cooperative effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 150000003904 phospholipids Chemical class 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000283923 Marmota monax Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 235000009001 Quillaja saponaria Nutrition 0.000 description 3
- 206010048937 Vaginal lesion Diseases 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000007949 saponins Chemical group 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241001092142 Molina Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241001454523 Quillaja saponaria Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 229940101578 microlipid Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- HFYWOOUKPVJGBA-UHFFFAOYSA-N 4-propan-2-ylquinoline Chemical compound C1=CC=C2C(C(C)C)=CC=NC2=C1 HFYWOOUKPVJGBA-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001038317 Homo sapiens VIP36-like protein Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000694414 Sapindus saponaria Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100040248 VIP36-like protein Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
經濟部中央標準局員工消費合作社印製 515715 A7 B7 五、發明説明(3 ) A,也稱爲3D-MPL)。由英國專利第2 220 211號(Ribi)得知, 3D-MPL就像三種類型的De_0-醯基化之單磷酸脂A與4、5或 酉&基化鏈的混合物一樣,並由Ribi Immunochem,Montana製 造。較佳的形式揭示於國際專利申請案第92/116556號中。 本發明中適當的組合物,是其中開始製備微脂粒時不含 MPL,然後再加入MPL的那些,而MPL最好是100毫微米的 顆粒。因此在囊膜之中不含有MPL(稱爲MPL在外)。其中含 有在囊膜之内的MPL之組合物(稱爲MPL在内),也形成本發 明的目標。所含有的抗原可在囊膜之内或在囊膜之外。較 好是可溶解的抗原在外側,而忌水性或經過脂化之抗原則 可包含在囊膜之内或其外側。 通常本發明之疫苗不需要任何特定的載劑,並在含水的 或其他藥學可接受之緩衝溶液中調配。在一些案例中,本 發明之疫苗進一步含有明蓉或存在於水包油型乳劑或其他 適當的媒劑中,可能是有利的,該適當媒劑像是例如微脂 粒、中心體或經過包膠的抗原顆粒。 較佳的疫苗調配物將含有能夠謗發對抗人類或動物病原 之免疫反應的抗原或抗原組合物。在本發明之組合物中, 可使用此項技藝中已知的抗原或抗原组合物,包括多醣抗 原、衍生自HIV-1 (諸如gpl20或gpl60等)的抗原或抗原組合物 、任何的免疫缺乏病毒、人類或動物的苑療病毒,諸如 gD或其衍生物,或是速早蛋白,如得自HSV1或HSV2的 ICP27、巨細胞病毒(特別是人類的)(如gB或其衍生物)、帶 狀水痘病毒(如gpl、II或III),或肝炎病毒之形式,如B型肝 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) -------訂-- 515715 A7 B7 五、發明説明(4 ) (請先閲讀背面之注意事項再填寫本頁) 炎病毒,例如B型肝炎表面抗原或其衍生物、A型肝炎病毒 、C型肝炎病毒和E型肝炎病毒,或其他病毒病原之形式, 如呼吸道融合細胞病毒(例如揭示於美國專利5,149,650號中 的HSRV F和G蛋白及其免疫原性之片段,或揭示於美國專 利第5,194,595號中,含有得自1181^蛋白質?和(3,6§?0糖蛋 白的嵌合多肽類)、衍生自腦膜炎品系的抗原,如腦膜炎A 、8和C,肺炎鏈球菌、人類乳頭狀瘤病毒、流行性感冒病 毒、嗜血性流行性感冒B(Hib)、愛氏頓病毒(EBV),或衍生 自細菌性病原者,如沙門桿菌屬、奈瑟球菌屬、螺旋體屬 (Borrelia)(例如OspA或OspB或其衍生物),或是衣形菌屬或博 德氏菌屬,例如P.69、PT和FHA,或衍生自寄生蟲者,如瘧 原蟲或毒漿體(toxoplasma)。 經濟部中央標準局員工消費合作社印製 HSV糖蛋白D(gD)或其衍生物是較佳的疫苗抗原。它位在 病毒膜上,亦在受感染之細胞的細胞質中發現它(Eisenberg R.J.等人;J of Virol 1980拉428-435)。其由393個胺基酸構 成,包括一個信號肽,並具有大約60kD的分子量。大概所 有HSV被膜糖蛋白均具有最佳的特性(Cohen等人J. Virology ㊇157-166)。在活體内,已知其在病毒附著細胞膜時扮演主 要的角色。然而,已經顯示糖蛋白D能夠在活體内謗發中 和抗體,並保護動物免於致命的挑戰。截短形式之gD分子 缺乏C終端的固定區域,並可在哺乳動物細胞中以可溶性 蛋白質之形式產製,再將其輸出到細胞培養基的上清液中 。這類可溶性形式的gD是較佳的。在歐洲專利0,1 3 9,4 1 7 號中描述了截短形式之gD的產製。gD最好是衍生HSV-2 -7- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 515715 A7 B7 五、發明説明(5 ) 。本發明的一個具體實施例爲具有3 0 8個胺基酸的經過截 短之H S V - 2糖蛋白D,其包括含有從1到3 0 6之天然存在的 胺基酸的糖蛋白,並在經過截短、缺乏其膜固定區域之蛋 白質的C終端處帶有額外的天冬醯胺和穀胺醯胺。這種形 式之蛋白質包含了信號肽,將其切開以容許從宿主細胞中 分泌出成熟的可溶性2 8 3胺基酸蛋白質。 在本發明另外的觀點中,Β型肝炎表面抗原也是較佳的疫 苗抗原。 當此處使用ΠΒ型肝炎表面抗原”或"HBsAg”之措辭時,包 括任何HBsAg抗原或其表現出HBV表面抗原之抗原性的片段 。將瞭解到,除了 226個胺基酸序列的HBsAg抗原(參見 Tiollais等人,Nature,317,489(1985)並在此作爲參考)之外 ,如同此文中描述的HBsAg,若需要可含有全部或部份的 在上述參考文獻中和在歐洲專利-A-0 278 940號中描述的-S 前序列。特定而言,HBsAg可包括含有下列胺基酸序列的 多肽,該胺基酸序列包括在ad血清型之B型肝炎病毒上,與 打開密碼有關之HBsAg的L-蛋白質的殘基12-52,隨後是殘 基133-145,再來是殘基175-400(該多肽也叫作L* ;參見歐洲 專利0 414 374號)。在本發明範圍内的HBsAg也可以包含歐 洲專利0 198 474號中描述的-S1-S2-S多肽(Endotronics)及其密 切類似物,如歐洲專利0 304 578號中描述的那些(Me Cormick和Jones)。此處描述之HBsAg也可以適用於突變體, 例如描述於WO91/14703或歐洲專利申請案第0 51 1 855A1號 中的1逃逸突變體’,特別是其中在位置145處有由甘胺酸對 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) ---II-----. 515715 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(6 精胺酸進行胺基酸取代的HBsAg。 HBsAg通常是顆粒形式的。顆粒可能僅含有例如蛋白質 ,或可以是综合的顆粒,例如(L*,S),其中L*如同上述之 定義,且S代表HBsAgi S_蛋白質。該顆粒以此形式可有利 地在酵母中表現出來。 令人滿意地證明了 B型肝炎表面抗原S-蛋白質的製備。參 見例如 Harford等人(1983),在 Develop. Biol. Standard 54,第 125 頁中、Gregg等人(1987),在Biotechnology 5,第 479 頁中、 歐洲專利0 226 846號、歐洲專利0 299 108號,並在此作爲參考。 在本發明範圍中的調配物也可以含有抗-腫瘤的抗原,並 在免疫治療上用來治療癌症。 疫苗製品通常描述於Voller等人編輯的New Trends and Developments in Vaccines,University Park Press,Baltimore ’ Maryland,U.S.A. 1987中。包膠到微脂粒中的作用則由例如 Fullerton描述於美國專利第4,235,877號中。蛋白質對巨分子 的共軏作用則由例如Likhite描述於美國專利第4,372,945號中 ,以及由Armor等人描述於美國專利第4,474,了57號中。 在每個疫苗劑量中蛋白質的用量,係按照在典型免疫反 應中能引起免疫保護反應,但沒有重大不利之副作用的用 量來選擇。這類用量將依據所使用的特定免疫原及其如何 表達來加以改變。通常期望每個劑量將含有卜1 000mCg的 蛋白質,較佳的是2-l〇〇mcg,最好是4_40mcg。特殊疫 苗的最佳用量,可藉著涉及在患者身上觀察適當之免疫反 應的標準研究來探知。在最初的疫苗接種之後’可使患者 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
經濟部中央標準局員工消費合作社印製 515715 A7 __— —____B7 五、發明説明(7 ) 接雙一或數次保持適當間隔的補強免疫作用。 本發明之調配物或許可用於預防和治療兩種目的中。 根據更進一步的觀點,因此本發明提供本發明之疫苗在 治療人類患者方面的用途。本發明提供一種治療方法,其 包括對患者投予有效量的本發明之疫苗。特定而言,本發 明提供一種治療病毒、細菌、寄生蟲感染或癌症的方法, 其包括對患者投予有效量的本發明之疫苗。 以下列實例和數據解釋本發明。 實例 1.1製備微脂粒的方法: 在眞空下(或另外在惰性氣體的蒸氣下),使在有機溶劑 中的脂質(諸如得自卵黃或合成的磷脂醯膽鹼)與膽固醇的混 合物脱水。然後加入含水的溶液(如磷酸緩衝的生理鹽水), 並搖動容器,直到所有的脂質均懸浮爲止。然後使該懸浮 液微流體化,直到微脂粒的大小減少到1 00毫微米爲止,並 通過0.2微米之濾紙進行無菌過濾。擠壓或聲波振盪可取代 此一步驟。 通常膽固醇:磷脂醯膽鹼的比例爲1 : 4(重量/重量),益 加入含水的溶液,而獲得5到50毫克/毫升的終膽固醇濃度 。如果在含有脂質的有機溶液中,加入在有機溶液中的 MPL ’則最後的微脂粒在膜中會含有]VIPL(稱爲MPL在内)。 具有100毫微米之限定大小的微脂粒,被稱爲SUV(小的單層 囊泡)。若重複冷凍並融解該溶液,囊泡合會融合而形成的 大的多層結構(MLV),其具有從500毫微米到15微米之大小 -10-
________________^^J 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) -----_---訂-----▲ 515715 A7 B7 五、發明説明(8 ) 經濟部中央標準局員工消費合作社印製 。微脂粒本身對於時間而言是穩定的,且沒有融合的能力 〇 1·2調配物程序: 在微脂粒中加入在含水之溶液中的QS21。然後將該混合 物加至抗原溶液中,如果需要其可含有以1〇〇亳微米顆粒之 形式存在的MPL。 1 · 3藉著含有膽固醇的微脂粒,抑制QS21的溶解活性 當將QS21加至紅血球中時,紅血球溶解而釋出紅血素。 每種溶解活性也可以利用在其膜内含有膽固醇的微脂粒和 被捕捉的螢光染料,羧基螢光素來測定之―當微脂粒被溶 解而釋放出可由螢光光譜監視的染料。若螢光微脂粒在其 膜中未含有膽固醇,則沒有觀察到微脂粒的溶解作用。八 如果在將QS21加至紅血球之前,先將㈨幻與含有膽固醇 的微脂粒一起培養,則紅血球的溶解會隨著膽固醇對qs21 之比例而減少。若使用〗:Ϊ之比例,則檢測不到溶解活性 。若微脂粒不含膽固醇,則抑制溶解作用需要超過卜 1000倍過量的磷脂。 同樣適用於使用螢光微脂粒來測定溶解活性。在下圖中 ,以螢光來測定經利用缺乏膽固醇(每赛 _ 回 、巧Γ毛升含1耄克的卵黃 卵磷脂)或含有膽固醇(每毫升含1毫克卵磕 、 ^ I ,脂和500微克膽固 醇)之微脂粒處理過的4微克QS2!之溶解、、舌座 (請先閱讀背面之注意事項再填寫本頁) 訂 -11 - 各紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 515715 A7 _ B7 五、發明説明(1G) (請先閲讀背面之注意事項再填寫本頁) 著在逆相HPLC上測量符合QS21之峰値的減少來監視之。例 如,下圖顯示在pH値9和溫度37°C,90%的QS21會在16小時 内水解。如果以2 : 1之比例(膽固醇:QS21重量/重量)在 QS21中加入含有膽固醇的微脂粒,則在同樣的條件下未檢 測出QS21的水解。如果該比例爲1 : 1,則有10%的QS21會 降解。 在37°C下在含有膽固醇之SUV的存在下,在 pH値9下培養2〇微克QS21 16小時
經濟部中央標準局員工消費合作社印製 結論是當QS21與含有膽固醇之微脂粒連結時,它會變的 較不易受到鹼-調節之水解作用的影響。當以非經腸方式給 予時,水解產物被描述爲不具佐劑活性,因此含有QS21的 疫苗必須在酸性的p Η値下調製,並存放在4 °C下來保護佐 劑組合物。而微脂粒的使用可以克服此一需求。 1 . 5反應原性之研究: -13- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715 A7 B7 五、發明説明(11 ) 在老鼠脛骨肌中注射5微克QS21(或毛地黃皂甞),加上漸 增量的微脂粒(以換算成膽固醇的微克量來表示之)。以相 當於QS21的微克量來表示溶解活性,其意指達到與試樣相 同的溶血所需的QS21量。 在肌肉注射部位的發紅、壞死和毒性,在犧牲老鼠之後 以目視記錄之。 調配物 溶解活性微克 發紅 壞死 毒性 QS21+PBS 5 +++ 士 +++ QS21+1微克膽固醇(SUV) 4 -H-+ + ++++ QS21 +5微克膽固醇(SUV) 0 麵 士 QS21 +25微克膽固醇(SUV) 0 土 + 僅有SUV 0 画 一 一 毛地黃皂甞 5 讀 土 PBS 0 一 麵 幢 數據顯示,當藉著添加含有膽固醇的微脂粒而廢除了溶 解活性時,因QS21而引起之毒性也被廢除了。 經濟部中央標準局員工消費合作社印製 1 . 6在兔子身上以肌肉内注射時的反應原性 U.I./L中的値 -14- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715
7 B 五、發明説明(12 ) 經濟部中央標準局員工消費合作社印製 實驗 調配物 第0天 溶血 第1天 溶血 第3天 溶血 兔子編號1 1078 + 8650 1523 兔子編號2 1116 4648 1435 兔子編號3 QS21 50微克 660 4819 684 兔子編號4 592 5662 684 兔子編號5 3400 7528 1736 平均値 1369 6261 1212 標準差 1160 1757 495 實驗 調配物 第0天 溶血 第1天 溶血 第3天 溶血 兔子編號6 596 1670 460 兔子编號7 QS21 50微克 540 602 594 兔子編號8 在SUV中的膽 611 1873 803 兔子編號9 固醇50微克 521 507 616 兔子編號10 (1:1) 1092 + 787 555 平均値 672 1088 606 標準差 238 636 125 (請先閲讀背面之注意事項再填寫本頁) -15-本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715 A7 B7五、發明説明(13 ) 實驗 調配物 第0天 溶血 第1天 溶血 第3天 溶血 兔子編號11 332 344 387 兔子編號12 QS21 50微克 831 662 694 兔子編號13 在SUV中的膽 464 356 519 兔子編號14 固醇150微克 528 720 614 兔子編號15 (1:3) 1027 568 849 平均値 637 530 613 標準差 285 173 175 經濟部中央標準局員工消費合作社印製 實驗 調配物 第0天 溶血 第1天 溶血 第3天 溶血 兔子編號16 540 769 745 兔子編號17 QS21 50微克 498 404 471 兔子編號18 在SUV中的膽 442 717 (4535) 兔子編號19 固醇250微克 822 801 925 兔子編號20 (1:5) 3182 土 2410 960 平均値 1097 1020 775 (1527) 標準差 1175 793 224 (1692) -16- (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715 A7 B7 五、發明説明(14 ) 實驗 調配物 第0天 溶血 第1天 溶血 第3天 溶血 兔子編號21 321 290 378 兔子編號22 660 535 755 兔子編號23 PBS 650 603 473 兔子編號24 1395 (3545) (5749) 兔子編號25 429 土 323 263 平均値 691 438 (1059) 467 (1523) 標準差 419 155 (1396) 210 (2369) (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 數據顯示,在調配物中添加含有膽固醇的微脂粒,明顯 地減少了由QS21所引之CPK(磷酸肌酸酶)的高度。因爲 CPK增加是肌肉損傷的程度,這表示降低了肌肉的損傷, 並藉著组織病理學來證實。 1。7微脂粒-QS21複合物對明礬的結合。 將QS21與含有過量膽固醇和具放射線活性之膽固醇的中 性微脂粒一起培養,然後與在PBS中的明礬(A1(0H)3)—起培 養。當單獨的時候,中性的微脂粒或QS21皆不與P B S中的 明礬結合,而只有帶負電荷的微脂粒與之結合。然而當同 時在一起時,QS21和中性微脂粒均與明礬結合。上清液中 不含QS21(藉著地衣酚試驗來分析),也不含具放射線活性 的膽固醇。 這顯示QS21已經與微脂粒結合,並允許微脂粒-QS21的組 合與明礬結合。這可能起因於QS21將負電荷加在微脂粒上 -17- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715 A7 B7 五、發明説明(15 ) ,或是暴露出微脂粒上的忌水性區域。結果也暗示QS21未 從膜中引出膽固醇。 (請先閲讀背面之注意事項再填寫本頁) 這表示本發明之組合物可被用在以明礬爲基礎的疫苗中 〇 1.8就抗體和CMI的謗導,比較微脂粒之QS21/MPL和自由的 QS21+MPL藉著壓擠來製備SUV (EYPC :膽固醇:MPL 20 : 5 : 1)。 關於MPL在外,製備不含MPL的微脂粒,再加入100毫微 米之顆粒大小的MPL。 在加入抗原之前先加入QS21。膽固醇:QS21=5 : 1 (重量 /重量)。 藉著在加入抗原之前,先將SUV冷凍-融解三次,來製造 MLV。 爲了要使抗原被捕捉,在冷凍-融解之前先加入抗原,並 在冷凍-融解之後再加入QS21。抗原包膠作用=5%在内, 95%在外。 經濟部中央標準局員工消費合作社印製 -在老鼠的腳蟄中注射兩次(關於gD使用balb/c品系的老鼠, 關於RTSs則使用B10BR品系的老鼠)。gD爲得自單純疱疹病 毒的糖蛋白D。RTSs爲以基因方式修改的B型肝炎表面抗原 (HBsAg),而使其含有來自鐮狀癔原蟲(Plasmodiium falciparum)種蟲的抗原決定位。 -18- 本紙張尺度適用中國國家標準(CNS ) A4規格(210'〆297公釐) 515715
A B 五、發明説明(16) 經濟部中央榡準局員Η消費合作衽印製
Ag(抗原)=1〇微克RTSs 抗HBsAg力價 在補強之後15天 調配物 IgGl IgG2a IgG2b SUV/QS+MPL(在外) +Ag 1175 10114 71753 MLV/QS+MPL(在外) +Ag 2247 11170 41755 MLV/QS+MPL(在内) +Ag 969 7073 18827 MLV/QS+MPL(在内)/Ag(在内)+Ag 1812 2853 9393 QS+MPL +Ag 372 9294 44457 Ag <100 <100 <100 SUV/QS+MPL (在外) <100 <100 <100 MLV/QS/MPL (在内) <100 <100 <100
Ag(抗原)=20微克gD 抗gD CMI 調配物 IgG IFN-,96 小時 (微微克/毫升) IL2 48小時 (微微克/毫升) SUV/QS+MPL(在外) +Ag 2347 1572 960 SUV/QS+MPL(在内) +Ag 2036 1113 15 MLV/QS+MPL(在外) +Ag 1578 863 15 MLV/QS+MPL(在内) +Ag 676 373 15 MLV/QS+MPL(在内)/Ag(在内)+Ag 1064 715 15 QS+MPL +Ag 1177 764 15 Ag <100 567 44 SUV/QS+MPL (在外) <100 181 15 MLV/QS/MPL (在内) <100 814 105 (請先閲讀背面之注意事項再填寫本頁) -19-本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) 515715 A7 B7 五、發明説明(17) (請先閱讀背面之注意事項再填寫本頁) 該數據顯示SUV/QS+MPL(在外),謗導出至少像qS21+mPL 一樣好的高抗體力價,以及謗導出細胞調節免疫的標記 IL 2,同時譽抑了 QS21的反應原性。 另外的結果顯示於下’遠結果係得自balb/c老鼠身上,以 HSV gD作爲抗原,比較QS21與在膽固醇(SUV)存在下的 QS21 : 同型第II次之後7天 調酉嫩 ίηΜ 第欠嫌天 (GMT) 第1D欠之後14天 (GMT) IgGl 微嫌斤 % IgG2a 微綠斤 % IgG2b % SUV/QS21+MPL 在外 gp&m 20290 16343 331 26 716 56 222 17 SUV/QS21/MPL 在内 gD(5f敗克) 12566 10731 418 44 412 44 111 12 QS21+MPL gD»克) 10504 10168 200 34 285 48 107 18 SUV/QS21+MPL 在外 無 0 0 0 0 0 0 0 0 QS21 gD(5f版克) 3468 4132 156 66 67 28 14 6 SUV/QS21 gD (滅) 11253 11589 484 57 304 36 65 8 1.9比較gpl20加微脂粒的MPL/QS21與自由的MPL/QS21 微脂粒=SUV在膜中含有MPL 膽固醇:QS21=6 : 1 在一次免疫接種之後兩週測試其反應 經濟部中央標準局員工消費合作社印製 調配物 增殖 IFN-g 毫微克/毫升 IL2 微微克/毫升 IL5 微微克/毫升 SUV/MPL/QS21+Ag 12606 16.6 59 476 MPL+QS21+Ag 16726 15.8 60 404 -20- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X297公釐) 經濟部中央標準局員工消費合作社印製 515715 A7 B7 五、發明説明(19 ) 這證實僅有QS21可謗導出CTL活性,而在含有膽固醇之微 脂粒的存在下,QS21謗導出至少和僅有QS21—樣好或更好 的CTL活性。 2 .疫苗 2.1 HBsAg L*,S顆粒的調配物 可依照下列方式來調製HBsAgL*,S顆粒: 在室溫下,在攪動之下培養10微克HBsAg L*,S顆粒/劑量1小 時。利用注射用水和PBS溶液來調整體積,達到帶有QS21水 溶液(10微克/劑量)的70微升/劑量之終體積。pH値保持在7土 0.5 〇 可利用1和5 0微克HBsAg L*,S來製備類似的調配物,亦使 用HBsAg S4元原。 可在Woodchuck代用品治療模式中測試這些調配物,利用 Woodchuck HBV抗原作爲模型。
Woodchuck 模式 可在Woodchuck治療模式中測試DQ QS21(也就是QS21/膽固 醇或受到壓抑的QS21),在其中以病毒慢性地感染動物。可 加入特定的Woodchuck肝炎病毒疫苗,與QS21本身,或是帶 有或不帶有MPL的DQ混合,並每個月投予動物一共6個月。 可經由病毒DNA清除作用來評估疫苗的效力。 2.2天竺鼠模式(HSV) 2.2.1預防模式 一組1 2隻雌性的Hartley天竺鼠,在第0天和第28天肌肉内 注射下列的調配物: -22- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁)
515715 A7 B7 五、發明説明(2G ) 第一個實驗: (請先閲讀背面之注意事項再填寫本頁) gD 5微克+QS21 50微克+含有50微克膽固醇的SUV gD 5微克+QS21 100微克+含有100微克膽固醇的SUV gD 5微克+QS21 50微克+含有250微克膽固醇的SUV gD 5微克+QS21 50微克 第二個實驗: §0 5微克+1^1?1^12.5微克+(^2112.5微克+含有62.5微克膽固 醇的SUV,或保留不加以處理。 在第二次免疫接種後第14和28天時將動物放血,並對其 gD-特異性之ELISA抗體力價進行血清測試。 然後利用1〇5 pfu個HSV-2MS品系,以陰道内之方式來挑戰 這些動物。從4到12天,每天對主要痕療病變的評估計分。 計分方式如下·· 陰道病變: -出血=0.5 -發紅一或兩天,但未出血=0.5 -發紅且出血一天=1 -發紅但未出血,持續3天=1 外部的疱疹水泡: 經濟部中央標準局員工消費合作社印製 -<4個小水泡=2 ->=4個小水泡或一個大水泡=4,>=4個大的病變=8,匯合的 大病變=16 •在整個外生殖器區域均有匯合的大病變=32。 結果顯示於下表中: -23- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 515715 A7 B7 五、發明説明(21 經濟部中央標準局員工消費合作社印製 Η-^ 1—A H-A ^ Η-A μ to to Ν> 一 bJ VI crq ciq 〇Q oq ^ σ σ σ σ 才、、' W % χ /Ο Ο /Ο /Ο E3 X GO CO OD 〇 ύ§ cn cn Ln cri t ??i > ^ ^ > Ο Ο Λ nr sr g. a a 〇 K ^ S ^ 沒有病變 的動物之 百分比 ° 〇 〇〇 i 陰道病變 發生率的 百分比 ui ^ 〇 SS ^ ^卜部病變 發生率的 百分比 馋2 * ,sgss 對對照組 的降低率 1__ 1.50 2.50 0.75 55.00 病變嚴 ,......_ 中間値 v〇 〇\ » as iirttli VW 口 * 物 丨+m 颯 s XTL < %% (請先閲讀背面之注意事項再填寫本頁) ----:---Ϊ1Τ------- -24- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 515715 A7 B7 五、發明説明(22 ) 經濟部中央標準局員工消費合作社印製 * 私韌淞菸4^12^3:孰飧茸今容箨命(^<%麵涔斜孰)«容》參)0 孰濰孳今”龄孰飧(0二醪麻孰飧(0.5涔1了岑者泠鉍夭浚(2-4“8^16) ** 澳淞鈦犛=翁命(鄭斤今»:ix(lf^^%);3ii=0-0.5 1r2 4 4 -S16 —· to to 、 3 is〜 < 調配物 Ϊ 47006 <400 EL] 第Π次之後 第14天 抗體力價;(GMT) 31574 <400 SA 第Π次之核 第28天 ί 八廿 U\ 4^ 〇 VO • %% t ^ h* c1^ 58,33 16.67 刮~择 今梦斜 ~ s m 1 1 33.33 8.33 . 陰道病變 發生率的 百分比 国1 8.33 75.00 外部病變 發生率的 百分比 • 1 37.50 丨 587.50 ‘ PI 指數# 主要疾病 94% 對對照組 的降低率 1.00 11.50 病變嚴i 中間値 〇 ^ 3 贪 * 碲棼2 -25» (請先閱讀背面之注意事項再填寫本頁)
木紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 515715 A7 B7 五、發明説明(23 ) 表和圖表顯示,在預防模式中,當以gD/MPL/QS21/SUV免 疫接種時,對主要疾病诱導出非常南程度的保護作用。外 部病變的發生率和病變嚴重性上,在以gD/MPL/QS21/SUV免 疫接種的動物組中顯示出高度的減少。 、2.2.2治療模式 在治療模式中,第一次以1〇5 pfu個HSVdMS品系挑戰雌性 的Hartley天竺鼠。然後將有痕療病變的動物隨機分成16隻 一組0 在第2 1天和第4 2天,以下列調配物其中一種來免疫牠們 -gD+MPL 50微克+QS21 50微克+含有250微克膽固醇的SUV, -gD+Al(OH)3+MPL 50微克+QS21 50微克+含有250微克膽固醇 的SUV或保留不加以處理。 從第22到75天,每天監視評估再發性疾病。計分方式按 照預防模式之描述。結果顯示於下表和圖表中: (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -26- 本紙張尺度適用中國國家標準(CNs ) A4規格(210 X 297公釐) 515715 A7 B7 五、發明説明(24 ) 治療模式: η 調配物 嚴, 中間値 f性* 對對照組 降低的% 期Η 中間値 對對照組 降低的% 偶發事利 中間値 卜數目*** 對對照組 降低的% 16 gD+MPL+QS21 9.00 43% 7.00 18% 3.00 14% +SUV 15 gD+Al(OH)3 + 8.50 46% 7.00 18% 3.00 14% MPL+QS21+SUV 16 未處理 15.75 8.50 3.50 * 感染後第22到75天的病變計分之總合。 (請先閱讀背面之注意事項再填寫本頁) ** 在感染後第22到75天,動物體驗到再發性疾病的總曰數 ***在感染後第22到75天,再發性偶發事件的數目。一個偶 發事件先發生,之後一天沒有病變,且其特徵爲出現 紅斑至少兩天(分數=0.5),或是出現外邵水泡一天(分數 >=2) 〇 在第21和42天時進行免疫治療的處理。 經濟部中央標準局員工消費合作社印製 結果顯示,在HSV-2感染的治療模式中也謗導出良好程度 的保護。以帶有或不帶有明礬的gD/MPL/QSZl/SUVf^疫,對 中間嚴重性的再發性疾病有明顯的效果。也稍微減少了偶 發事件的數量和期間(參見表中)。 -27- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) .公%. r _ 1,一 ,本 +請曰期 85.4.23 案 號 085104841 類 別 (以上各欄由本局填註) 修丨 A4, C4 中文說明書修正頁(91年f月)515715 || ^專利説明書 中 文 、爹明 新型 名稱 英 文 姓 名 國 籍 具有免疫活性QS21之疫苗組合物 VACCINE COMPOSITIONS HAVING IMMUNOLOGICALLY ACTIVE QS21 1·納沙力·馬力-約瑟·克勞德·加肯 2·馬丁·佛萊德 發明 創作 人 住、居所 國 籍 1.法國 2,英國 均比利時利克森沙特市第一學院路89號 裝· 三、申請人 住、居所 (事務所) 比利時商史密斯克萊美占生物公司 比利時 比利時利克森吵特市弟一學院路89號 詹恩·史帝芬 本紙張尺度適财S國家鲜(CNS) Μ規格⑽χ 297公爱) 515715 第085104841號專利申請案 中文說明書修正頁(91年|月) 修ill丨 五、發明説明( ) 1 本發明係關於新穎的疫苗調配物·、其產製方法,及其在 醫學上的用途。特定而言,本發明係關於疫苗,其包括抗 原或抗原性組合物免疫活性之QS21,以犮固醇。 在此項技藝中,已知具有佐劑活性並具有免疫活性的皂 角嘗部份,係衍生自南美樹Quillaja Saponaria Molina的樹皮 。例如,QS21,也叫作 QA21,為一種從 Quillaja Saponaria Molina樹中,經Hplc純化的部份,及其產製方法,均揭示於 美國專利第5,057,540號(叫作QS21)。亦曾由Scott等人,Int. Archs. Allergy Appl. Immun·,1985,77,409揭示了皂樹可作 為佐劑。然而,使用QS21作為佐劑,與某種不利有關。例 如,當把自由分子之形式的QS21注射到哺乳動物體内時, 已經觀察到壞死,也就是說,在注射部位發生局部的組織 死亡。 現在已經意外地發現,藉著使用含有QS21與固醇混合的 調配物,可避免注射部位的壞死。較佳的固醇包括/3 -麥胚 脂醇、豆脂醇、麥角留醇、麥角鈣化留醇和膽固醇。這些 固醇類為此項技藝中已熟知的,例如膽固醇被揭示於Merck Index,第11版,341頁,被發現是一種天然存在於動物脂質 中的固醇。 因此本發明的主要觀點是提供一種疫苗組合物,其包括 抗原、具有.免疫活性的皂角苷部份和固醇。本發明之組合 物較好是包含大體上為純粹形式的皂角甞部份。最好是本 發明之組合物含有大體上為純粹形式之QS21,也就是說, 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
裝
515715 第85104841號專利申請案 I ~ 中文說明書修正頁(90年1〇月) Α7
QS,純度至少為90%,較佳的是純度至少為95%,而最佳 的疋純度至少為98% °其他可使用於本發明組合物中, 免後活性的m部份包括QA17/QS17。含有讲21和膽固醇 的本發明組合物,當與缺乏膽固醇之組合物相比較時,顯 π出降低的反應原性,同時乃保留佐劑效力。除此之外, 已知(^21在?11值約為7或更高的驗性條件下會降解。本發明 化合物具有更多的優點,就是在含有膽固醇的調配物中, 促進了 QS21對驗-調節之水解作用的穩定性。 本發明中較佳的組合物是形成微脂粒結構的那些。 QS21 :固醇的比例,通常將按照以重量計丨:1〇〇到1 ··工的 順序。較佳的是出現過量的固醇,QS21 :固醇之比例至少 為1 · 2的重量/重量。代表性對人類投藥用的1和固醇, 在疫苗中將以每個劑量出現大約丨微克到大約100微克之間 ’幸父佳的是大約10微克到大約50微克之間。 微脂粒最好是含有中性的脂質,例如磷脂醯膽鹼,最好 疋在室溫下無結晶的,例如卵黃磷脂醯膽鹼、二油醯磷脂 酿膽驗或二月桂基磷脂醯膽驗。微脂粒也可以含有帶電荷 的脂質,其增加微脂粒-QS2U#構對於由飽和脂質構成之微 脂粒的穩定性。在這些案例中,帶電荷脂質的量,較佳的 是1-20%重量/重量,最好是5··1〇%。而固醇對磷脂的比例為 1-50%(莫耳/莫耳),最好是20-25%。 本發明中較佳的組合物含有MPL(3-脫醯基化的單-磷酸脂 ___ -5- 本纸張尺度適用中國國家標準⑴!^^ A4規格(21〇χ 297公釐)
裝* % 515715 第85104841號專利申請案 中文説明書修正頁(87年9月) A7 B7
五、發明説明(9) 比較以含有或缺乏膽固 醇之微脂粒壓抑的QS21
Γ (窆贫鋈轻)J
微脂粒的微升量
(請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 數據顯示,以特定方式與在膜中之膽固醇連結的QS21, 因此而引起(細胞或螢光微脂粒)的溶解。 若先使QS21與膽固醇在微脂粒中連結,則其不再使細胞 或其他微脂粒溶解。所需要的最低比例爲0.5 : 1的膽固醇: QS21(重量/重量)。 膽固醇在含水的溶液中是不可溶的,且不會形成穩定的 懸浮液。當磷脂存在時,膽固醇存在於鱗脂雙層之中,可 形成穩定的囊泡懸浮液,稱作微脂粒。要避免加入鱗1脂的 需求,嘗試可溶性的衍生物。多氧乙烯基膽固醇癸二酸酯 能夠以60毫克/毫升之濃度而溶於水中,然而即使其超過 QS21的2000倍過量(重量/重量),也不能檢測到QS21溶解活 性的減少。 1.4藉著含有膽固醇之微脂粒來增加QS21的穩定性。 QS21在pH値高於7時是非常容易水解的。該水解作用可藉 12- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 515715 第85104841號專利申請案' A7. 厂杉正 中文説明書修正頁(87年9月)_Β7_1^ 充 五、發明説明(18) 在第二次免疫接種之後: 調配物 增殖 IFN-g IL4 IL5 毫微克/毫升 微微克/毫升 微微克/毫升 SUV/MPL/〇S21+Ae 12606 135 0 250 MPL+QS21+As 16726 60 0 500 (請先閱讀背面之注意事項再填寫本頁) 該數據顯示與含有膽固醇之微脂粒和MPL連結的QS21, 謗導出相當於MPL+QS21的Thl/ThO反應。 以這樣的膽固醇對QS21之比例,QS21對兔子是無毒性的(由 CPK得知)。 在第二個實驗中,在QS21或QS21 +含有膽固醇之SUV的存 在下,利用gpl20以腳塾内注射之方式來免疫balb/c老鼠。·測 量在脾臟細胞中胞毒T-淋巴球的活性。 yp!20 +QS21 經濟部中央標準局員工消費合作社印製 □Kfi—Tf 5 Ό 5 ο 5 2 2 11 ——Ρ815 —〇—Ρ815 + Ε7 gpl20 +QS21 +SUV 0050432020100
——P8) •5 —σ—Ρ81 5 + Β7 〇. C3 ΓΊ 〇 Q CO ^ ” O' 效為物/目標之比例 效應物:蛀標i比例:: -21 - 本紙張尺度適用中國國家標準(CNS)A4規格(210X 297公釐)
Claims (1)
- 中文i1^4^41號專利申請案 —專利範圍修正太⑼年^月)申請專利範圍 A8 B8 C8 D8 Π1 % ¥ Η種疫苗組合物,包括抗原或抗原性組合物、Q S 2 1和固 醇’特徵在於QS21對固醇之比例為1 ·· 1至1 : 100(w/w) 〇 2 ·根據申請專利範圍第1項之疫苗組合物,其中Q S 2 1對固 醇之比例為1 : 1至1 : 5(w/w)。 3 ·根據申請專利範圍第1項之疫苗組合物,其中Q S 2 1對固 辱之比例為1 : 2 (w / w)。 4 ·根據申請專利範圍第1項之疫苗組合物,其中該固醇為 膽固醇。 5 ·根據申請專利範圍第1項之疫苗組合物,其另含有3去- 〇-酿基化單磷酸酯A (3D-MPL)。 6 ·根據申请專利範圍第1項之疫苗組合物,其另含一載劑 〇 7.根據申請專利範圍第6項之疫苗組合物,其中載劑選自含 油落於水乳劑、明礬、微球體及抗原被包囊顆粒之群組 〇 8 ·根據申請專利範圍第1項之疫苗組合物,其中該Q s 2 i係 呈脂小體結構。 9 ·根據申請專利範圍第8項之疫苗組合物,其中該卩$ 2 1之 純度大於95 %。 ι〇·根據申請專利範圍第9項之疫苗組合物,其中該Qs2ii 純度大於9 8 %。 1 1 .根據申請專利範圍第8項之疫苗組合物, MPL包含於該脂小體中。 ^ 51571f A B c D 、申請專利祀圍 1 2 .根據申請專利範圍第1項之疫苗\组合物,其中該抗原或 抗原性組合物衍生自:任何人類的免疫缺乏病毒、貓的 免疫缺乏病毒、帶狀水痘病毒、單純⑴療病毒1型、單純 ⑴疹病毒2型、人類巨細胞病毒、A、B、C或E型肝炎、 呼吸道融合細胞病毒、人類乳頭狀瘤病毒、流行性感冒 病毒、Hib、腦膜炎病毒、沙門桿菌屬(Salmonella)、奈瑟 球菌屬(Neisseria)、螺旋體屬(Borrelia)、衣形菌屬 (Chlamydia)、博德氏菌屬(Bordetella)、癔原蟲(Plasmodium) 或毒漿體(Toxoplasma)。 1 3 .根據申請專利範圍第1至7項之疫苗組合物,另包括衍生 自腫瘤之抗原。 1 4 .根據申請專利範圍第1至7項之疫苗組合物.,用於醫藥品 〇 1 5 .根據申請專利範圍第1至7項之疫苗組合物,用於病毒、 細菌或寄生蟲感染之預防性治療。 1 6 .根據申請專利範圍第1至7項中任一項之疫苗組合物,用 於癌症之免疫醫療處理。 1 7 . —種使Q S 2 1對於碱引發性水解安定之方法,其包括使 Q S 2 1與含固醇之脂小體混合。 1 8 . —種使Q S 2 1對於碱引發性水解安定之方法,其包括使 Q S 2 1與固醇以1 : 1至1: 1 0 0之重量比混合。 1 9 .根據申請專利範圍第1 7或1 8項之方法,其中該固醇為膽 固醇。 2 0 . —種製備根據申請專利範圍第1項之疫苗組合物之方法, -2- 本紙張尺度適用中國國家標準(CNS) A4規格(210 x 297公釐)515715 8 8 8 8 A BCD 六、申請專利範圍 其包括下列步騾: a) 製備含有固醇之脂質懸浮液; b) 使該脂質懸浮液微流體化,直至脂小體之體積降低至 1 0 0 nm ;及 c) 力π 入 QS21 〇 2 1 . —種製造根據申請專利範圍第1項之疫苗組合物的方法 ,其包括將Q S 2 1和膽固醇,與抗原或抗原性組合物混合 -3- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9508326.7A GB9508326D0 (en) | 1995-04-25 | 1995-04-25 | Vaccines |
GBGB9513107.4A GB9513107D0 (en) | 1995-06-28 | 1995-06-28 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
TW515715B true TW515715B (en) | 2003-01-01 |
Family
ID=26306923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW85104841A TW515715B (en) | 1995-04-25 | 1996-04-23 | Vaccine compositions having immunologically active QS21 |
Country Status (37)
Country | Link |
---|---|
EP (3) | EP0884056A1 (zh) |
JP (1) | JP3901731B2 (zh) |
KR (1) | KR100463372B1 (zh) |
CN (3) | CN1248737C (zh) |
AP (1) | AP771A (zh) |
AR (1) | AR001686A1 (zh) |
AT (2) | ATE373487T1 (zh) |
AU (2) | AU693022B2 (zh) |
BG (1) | BG63491B1 (zh) |
BR (1) | BR9608199B1 (zh) |
CA (1) | CA2217178C (zh) |
CY (1) | CY2588B2 (zh) |
CZ (1) | CZ296216B6 (zh) |
DE (2) | DE69605296T3 (zh) |
DK (2) | DK0955059T3 (zh) |
DZ (1) | DZ2026A1 (zh) |
EA (1) | EA000839B1 (zh) |
ES (2) | ES2293708T3 (zh) |
GR (1) | GR3031912T3 (zh) |
HK (2) | HK1009086A1 (zh) |
HU (1) | HU227944B1 (zh) |
IL (1) | IL118004A (zh) |
MA (1) | MA23850A1 (zh) |
MY (1) | MY134811A (zh) |
NO (1) | NO322190B1 (zh) |
NZ (1) | NZ305365A (zh) |
OA (1) | OA10629A (zh) |
PL (1) | PL184061B1 (zh) |
PT (1) | PT955059E (zh) |
RO (1) | RO119068B1 (zh) |
SA (1) | SA96170297B1 (zh) |
SI (2) | SI0955059T1 (zh) |
SK (1) | SK282017B6 (zh) |
TR (1) | TR199701252T1 (zh) |
TW (1) | TW515715B (zh) |
UA (1) | UA56132C2 (zh) |
WO (1) | WO1996033739A1 (zh) |
Families Citing this family (494)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AUPO732997A0 (en) * | 1997-06-12 | 1997-07-03 | Csl Limited | Ganglioside immunostimulating complexes and uses thereof |
US6645495B1 (en) * | 1997-08-29 | 2003-11-11 | Antigenics, Inc. | Compositions of saponin adjuvants and excipients |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
GB9724531D0 (en) | 1997-11-19 | 1998-01-21 | Smithkline Biolog | Novel compounds |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
PT1584685E (pt) | 1998-02-05 | 2011-06-17 | Glaxosmithkline Biolog Sa | Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
KR100797876B1 (ko) | 1998-04-07 | 2008-01-24 | 코릭사 코포레이션 | 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP2272859B1 (en) | 1998-08-07 | 2014-10-22 | University of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
CA2347099C (en) | 1998-10-16 | 2014-08-05 | Smithkline Beecham Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
WO2000034482A2 (en) | 1998-12-08 | 2000-06-15 | Smithkline Beecham Biologicals S.A. | Novel compounds derived from neisseria meningitidis |
WO2000034483A2 (en) | 1998-12-08 | 2000-06-15 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6579973B1 (en) | 1998-12-28 | 2003-06-17 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
CA2371994C (en) * | 1999-02-26 | 2010-09-28 | Guido Grandi | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
EP2270169A3 (en) | 1999-03-12 | 2011-06-15 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
HU228499B1 (en) * | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
NZ514818A (en) | 1999-04-02 | 2004-04-30 | Corixa Corp | Compounds and methods for therapy and diagnosis of lung cancer |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
TR200103018T2 (tr) * | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
US6432411B1 (en) * | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
JP4540033B2 (ja) | 1999-10-22 | 2010-09-08 | サノフィ パストゥール リミテッド | 腫瘍抗原に対する免疫応答を誘発および/または増強する方法 |
AU2243801A (en) * | 1999-12-08 | 2001-06-18 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
US6905712B2 (en) | 1999-12-08 | 2005-06-14 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminum salt |
PT1265915E (pt) | 2000-02-23 | 2011-02-07 | Glaxosmithkline Biolog Sa | Novos compostos |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
DE60134499D1 (de) * | 2000-04-13 | 2008-07-31 | Corixa Corp | Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten |
DE60133190T2 (de) | 2000-04-21 | 2009-04-02 | CORIXA CORP., Wilmington | Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen |
ATE513913T1 (de) | 2000-05-10 | 2011-07-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
WO2001098460A2 (en) | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
AU2001273149A1 (en) | 2000-06-28 | 2002-01-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
CZ20024224A3 (cs) | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
ES2377077T3 (es) | 2000-10-18 | 2012-03-22 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D |
CA2425358C (en) * | 2000-10-18 | 2012-08-21 | Glaxosmithkline Biologicals S.A. | A vaccine composition comprising qs21, mpl, a cpg oligonucleotide and a cancer antigen |
EP1201250A1 (en) * | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
AU2002248392A1 (en) * | 2001-01-26 | 2002-08-06 | Walter Reed Army Institute Of Research | Recombinant plasmodium falciparum merozoite protein-1/42 vaccine |
US7306806B2 (en) | 2001-01-26 | 2007-12-11 | United States Of America As Represented By The Secretary Of The Army | Recombinant P. falciparum merozoite protein-142 vaccine |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
US20040071734A1 (en) | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
US20040096463A1 (en) * | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
NZ530315A (en) | 2001-07-10 | 2007-01-26 | Corixa Corp | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
GB0118367D0 (en) | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
JP4592284B2 (ja) | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
CA2860702C (en) | 2001-12-17 | 2019-02-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
DE10211088A1 (de) | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
ATE514707T1 (de) | 2002-04-19 | 2011-07-15 | Univ Toronto | Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer |
CA2492598C (en) | 2002-07-18 | 2013-12-17 | University Of Washington | Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
JP4740738B2 (ja) | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
US8232255B2 (en) | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
PT1581812E (pt) | 2003-01-06 | 2008-09-22 | Wyeth Corp | Composições e métodos para diagnóstico e tratamento de cancros do cólon |
PL378001A1 (pl) * | 2003-01-29 | 2006-02-20 | Pfizer Products Inc. | Szczepionki przeciw Bordetella bronchiseptica dla psów |
US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
WO2004087204A2 (en) | 2003-04-04 | 2004-10-14 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
DE10341812A1 (de) | 2003-09-10 | 2005-04-07 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
EP1670506B1 (en) | 2003-10-02 | 2012-11-21 | Novartis AG | Liquid vaccines for multiple meningococcal serogroups |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CA2539715C (en) | 2003-10-02 | 2015-02-24 | Glaxosmithkline Biologicals S.A. | Pertussis antigens and use thereof in vaccination |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
CA2555274A1 (en) | 2004-02-05 | 2005-08-25 | The Ohio State University Research Foundation | Chimeric vegf peptides |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
CA2559371C (en) | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
ES2409782T3 (es) * | 2004-04-05 | 2013-06-27 | Zoetis P Llc | Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna |
EP1740217B1 (en) | 2004-04-30 | 2011-06-15 | Novartis Vaccines and Diagnostics S.r.l. | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1766034B1 (en) | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
CA2837748C (en) | 2004-05-25 | 2016-03-08 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors |
AU2005249212B2 (en) | 2004-05-28 | 2010-05-20 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
US20090317420A1 (en) | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
GB0420634D0 (en) * | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
NZ553776A (en) | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
AU2005294129B2 (en) | 2004-10-08 | 2010-12-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonymous codons |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP1835027B1 (en) | 2004-12-07 | 2015-02-25 | Toray Industries, Inc. | Novel cancer antigen peptide and the use thereof |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
EP1858919B1 (en) | 2005-02-18 | 2012-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immunogens from uropathogenic escherichia coli |
EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
CA2601022C (en) | 2005-03-23 | 2023-03-07 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
US8541007B2 (en) | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
EA014527B1 (ru) | 2005-03-31 | 2010-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против хламидиоза |
PL2457926T3 (pl) | 2005-04-29 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
JP5222134B2 (ja) | 2005-06-15 | 2013-06-26 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | Her−2ペプチド |
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP1910410B1 (en) | 2005-07-01 | 2011-10-26 | Forsyth Dental Infirmary for Children | Tuberculosis antigen detection assays and vaccines |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
GB0519871D0 (en) | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
WO2007047749A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
CN104474543A (zh) | 2005-11-01 | 2015-04-01 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP2368572B1 (en) | 2005-11-04 | 2020-03-04 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
DE102005059242A1 (de) | 2005-12-12 | 2007-06-14 | Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten | Molekulare Marker für eine Tumordiagnose und -therapie |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP3020411A1 (en) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Vaccine |
US9259463B2 (en) | 2006-01-16 | 2016-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Chlamydia vaccine |
UA92782C2 (ru) | 2006-01-17 | 2010-12-10 | Арне Форсгрен | Новый поверхностный белок haemophilus influenzae (белок е; ре) |
KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
US20100068223A1 (en) | 2006-03-24 | 2010-03-18 | Hanno Scheffczik | Storage of Influenza Vaccines Without Refrigeration |
EP1998802A2 (en) | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
KR20120042865A (ko) | 2006-03-30 | 2012-05-03 | 엠브렉스, 인코포레이티드 | 가금류의 예방접종 방법 및 조성물 |
CA2647942A1 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
EP2032719A2 (en) | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
EP2054431B1 (en) | 2006-06-09 | 2011-08-31 | Novartis AG | Conformers of bacterial adhesins |
EP2032161B1 (en) | 2006-06-12 | 2012-07-11 | GlaxoSmithKline Biologicals S.A. | L3v los vaccines |
EP2044104A2 (en) | 2006-06-29 | 2009-04-08 | Novartis AG | Polypeptides from neisseria meningitidis |
ES2469568T3 (es) | 2006-07-17 | 2014-06-18 | Glaxosmithkline Biologicals S.A. | Vacuna contra la gripe |
MX2009000650A (es) | 2006-07-18 | 2009-07-02 | Secretary Of The Army The Unit | Vacunas para malaria. |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
GB2453475B (en) | 2006-07-25 | 2011-01-19 | Secr Defence | Live vaccine strain |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
WO2008028957A2 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
DK2068918T4 (da) | 2006-09-26 | 2024-09-02 | Access To Advanced Health Inst | Vaccinesammensætning omfattende syntetisk adjuvant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
CA2664619C (en) | 2006-10-12 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent |
EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
US9040081B2 (en) * | 2006-11-20 | 2015-05-26 | Duecom | Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer |
PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
DK2136836T3 (en) | 2007-04-04 | 2017-04-10 | Infectious Disease Res Inst | Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
EP2152903A2 (en) | 2007-04-26 | 2010-02-17 | Ludwig Institute for Cancer Research, Ltd. | Methods for diagnosing and treating astrocytomas |
EA201490303A1 (ru) | 2007-05-02 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
ATE550347T1 (de) | 2007-05-25 | 2012-04-15 | Novartis Ag | Streptococcus pneumoniae pilus-antigene |
GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
PT2167121E (pt) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
HUE025149T2 (hu) | 2007-08-02 | 2016-01-28 | Biondvax Pharmaceuticals Ltd | Multimer multiepitóp influenza vakcinák |
CA2695421A1 (en) | 2007-08-03 | 2009-02-12 | President And Fellows Of Harvard College | Chlamydia antigens |
NZ583150A (en) | 2007-08-13 | 2012-05-25 | Glaxosmithkline Biolog Sa | Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria |
EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
WO2009037438A1 (en) | 2007-09-17 | 2009-03-26 | Oncomethylome Sciences Sa | Improved detection of mage-a expression |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
EP2213301B1 (en) | 2007-10-25 | 2017-12-06 | Toray Industries, Inc. | Immune response inducer |
EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
EP2722056A1 (en) | 2007-12-03 | 2014-04-23 | President and Fellows of Harvard College | CT062, a Chlamydia antigen |
WO2009117035A1 (en) | 2007-12-19 | 2009-09-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of hendra and nipah virus f glycoprotein and uses thereof |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
BRPI0821240B8 (pt) | 2007-12-21 | 2022-10-04 | Novartis Ag | formas mutantes de estreptolisina o |
ES2597439T3 (es) | 2007-12-24 | 2017-01-18 | Id Biomedical Corporation Of Quebec | Antígenos recombinantes del VSR |
AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
PT2271360E (pt) | 2008-04-16 | 2015-12-07 | Glaxosmithkline Biolog Sa | Vacina |
US9527906B2 (en) | 2008-04-18 | 2016-12-27 | The General Hospital Corporation | Immunotherapies employing self-assembling vaccines |
US9314515B2 (en) | 2008-04-25 | 2016-04-19 | Ludwig Institute For Cancer Research Ltd. | Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers |
EP2293813A4 (en) | 2008-05-23 | 2012-07-11 | Univ Michigan | NANOEMULSION VACCINES |
CA2733356C (en) | 2008-08-01 | 2016-06-07 | Gamma Vaccines Pty Limited | Influenza vaccines |
PL2837383T3 (pl) | 2008-08-05 | 2017-07-31 | Toray Industries, Inc. | Środek indukujący odporność |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
JP5722782B2 (ja) | 2008-09-26 | 2015-05-27 | ナノバイオ コーポレーション | ナノエマルジョン治療用組成物及びその使用方法 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
CN102239253A (zh) | 2008-12-03 | 2011-11-09 | 普罗蒂亚维仕尼科技有限公司 | 谷氨酰tRNA合成酶(GtS)片段 |
AU2010204139A1 (en) | 2009-01-12 | 2011-08-11 | Novartis Ag | Cna_B domain antigens in vaccines against gram positive bacteria |
GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
EA201500910A1 (ru) | 2009-02-10 | 2016-04-29 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
AU2010215595A1 (en) * | 2009-02-17 | 2011-08-25 | Glaxosmithkline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
EP2221375A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
CN107028969A (zh) | 2009-02-20 | 2017-08-11 | 加尼梅德药物公司 | 用于癌症诊断和治疗的方法和组合物 |
JP2012519482A (ja) | 2009-03-06 | 2012-08-30 | ノバルティス アーゲー | クラミジア抗原 |
BRPI1009873A2 (pt) | 2009-03-17 | 2016-03-08 | Glaxosmithkline Biolog Sa | detecção aperfeiçoada de expressão gênica |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
US8679505B2 (en) | 2009-04-14 | 2014-03-25 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
EP2249159A1 (en) | 2009-04-29 | 2010-11-10 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
EP3124491B1 (en) | 2009-06-05 | 2019-10-30 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
CA2765364C (en) | 2009-06-15 | 2015-05-26 | National University Of Singapore | Influenza vaccine, composition, and methods of use |
CN102596243B (zh) | 2009-06-16 | 2015-10-21 | 密执安大学评议会 | 纳米乳剂疫苗 |
MA33449B1 (fr) | 2009-06-24 | 2012-07-03 | Glaxosmithkline Biolog Sa | Antigènes recombinants du vrs |
CA2766205A1 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine comprising at least two paramyxovirus f protein antigens |
MX2012000395A (es) | 2009-07-07 | 2012-02-28 | Novartis Ag | Inmunogenos conservados de escherichia coli. |
ES2918381T3 (es) | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
JP2012532626A (ja) | 2009-07-16 | 2012-12-20 | ノバルティス アーゲー | 無毒化されたEscherichiacoli免疫原 |
EP2453903B1 (en) | 2009-07-17 | 2016-08-17 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
EP2471801A4 (en) | 2009-08-26 | 2013-12-04 | Rna Inc | GLYCOLIPIDES DERIVED FROM LIPOTHEICHOIC ACID AND COMPOSITIONS CONTAINING THESE GLYCOLIPIDS |
US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
US20120283115A1 (en) | 2009-08-31 | 2012-11-08 | Ludwig Institute For Cancer Research Ltd. | Seromic analysis of ovarian cancer |
US20110110980A1 (en) | 2009-09-02 | 2011-05-12 | Wyeth Llc | Heterlogous prime-boost immunization regimen |
SI2475384T1 (sl) * | 2009-09-10 | 2016-12-30 | Merial, Inc. | Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin |
CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
JP2013505022A (ja) | 2009-09-16 | 2013-02-14 | バクサート インコーポレーティッド | H1n1感染を予防するための免疫戦略の方法 |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
CA2776004A1 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
ES2812523T3 (es) | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8 |
WO2011040978A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
US20130022633A1 (en) | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
NZ734307A (en) | 2009-11-11 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (cldn6) |
EP2322555A1 (en) | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
ES2707778T3 (es) | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
BR112012022688A2 (pt) | 2010-03-10 | 2018-05-22 | Glaxosmithkline Biologicals Sa | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
EP2366709A1 (en) | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
AU2011229518B2 (en) | 2010-03-16 | 2015-09-24 | Biontech Protein Therapeutics Gmbh | Tumor vaccination involving a humoral immune response against self-proteins |
AU2011231574A1 (en) | 2010-03-26 | 2012-10-11 | Glaxosmithkline Biologicals S.A. | HIV vaccine |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
US9744228B2 (en) | 2010-04-07 | 2017-08-29 | Norvartis Ag | Method for generating a parvovirus B19 virus-like particle |
US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
WO2011149564A1 (en) | 2010-05-28 | 2011-12-01 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
EP3170508B1 (en) | 2010-06-04 | 2019-11-13 | Wyeth LLC | Vaccine formulations |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
DK2618835T3 (en) | 2010-09-20 | 2017-08-28 | Biontech Cell & Gene Therapies Gmbh | ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
TW201305190A (zh) | 2010-10-15 | 2013-02-01 | Glaxosmithkline Biolog Sa | 新穎之抗原 |
US20130345079A1 (en) | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
WO2012064659A1 (en) | 2010-11-08 | 2012-05-18 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
SI2651436T1 (sl) | 2010-12-14 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Mikrobakterijski antigenski sestavek |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
PT2667892T (pt) | 2011-01-26 | 2019-06-07 | Glaxosmithkline Biologicals Sa | Regime de imunização contra o vsr |
US20140079732A1 (en) | 2011-01-27 | 2014-03-20 | Gamma Vaccines Pty Limited | Combination vaccines |
US9303070B2 (en) | 2011-02-22 | 2016-04-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
US9321813B2 (en) | 2011-03-29 | 2016-04-26 | Uab Research Foundation | Methods and compositions for cytomegalovirus IL-10 protein |
GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
KR102072183B1 (ko) | 2011-05-13 | 2020-02-03 | 가니메드 파마슈티칼스 게엠베하 | 클라우딘 6을 발현하는 암 치료용 항체 |
JP2014519819A (ja) | 2011-05-13 | 2014-08-21 | ノバルティス アーゲー | 融合前rsvf抗原 |
SG194733A1 (en) | 2011-05-17 | 2013-12-30 | Glaxosmithkline Biolog Sa | Vaccine against streptococcus pneumoniae |
BR112013029704A2 (pt) | 2011-05-19 | 2017-08-29 | Toray Industries | Agente de indutor de imunidade e uso de um agente indutor de imunidade |
BR112013029596B8 (pt) | 2011-05-19 | 2022-02-08 | Toray Industries | Composição imunogênica |
DK3473267T3 (da) | 2011-05-24 | 2021-10-18 | BioNTech SE | Individualiserede vacciner mod cancer |
NZ730355A (en) | 2011-05-24 | 2022-10-28 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualized vaccines for cancer |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
EP2717909B1 (en) | 2011-06-04 | 2017-12-06 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
CA2837651A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
JP6088507B2 (ja) | 2011-07-08 | 2017-03-01 | ノバルティス アーゲー | チロシンライゲーションの方法 |
US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
GB201114919D0 (en) | 2011-08-30 | 2011-10-12 | Glaxosmithkline Biolog Sa | Method |
TR201909110T4 (tr) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler. |
SI2758432T1 (sl) | 2011-09-16 | 2019-07-31 | Ucb Biopharma Sprl | Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile |
US9493517B2 (en) | 2011-11-07 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Conjugates comprising an antigen and a carrier molecule |
EP2780034A1 (en) | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
CN108864291A (zh) | 2011-11-23 | 2018-11-23 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
DK2785683T3 (da) | 2011-11-30 | 2020-04-14 | Ludwig Inst For Cancer Res Ltd | Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
US20130236484A1 (en) | 2012-03-08 | 2013-09-12 | Detectogen Inc. | Leishmaniasis antigen detection assays and vaccines |
EP2833900B1 (en) | 2012-04-01 | 2018-09-19 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
CN107540730B (zh) | 2012-05-16 | 2021-07-16 | 免疫设计公司 | 用于hsv-2的疫苗 |
MX2014014067A (es) | 2012-05-22 | 2015-02-04 | Novartis Ag | Conjugado de serogrupo x de meningococo. |
EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
GB201213364D0 (en) | 2012-07-27 | 2012-09-12 | Glaxosmithkline Biolog Sa | Purification process |
HRP20240164T1 (hr) | 2012-08-03 | 2024-04-12 | Access To Advanced Health Institute | Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
US10232035B2 (en) | 2012-09-14 | 2019-03-19 | The Regents Of The University Of Colorado, A Body Corporate | Conditionally replication deficient herpes virus and use thereof in vaccines |
JP6283674B2 (ja) | 2012-09-18 | 2018-02-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 外膜小胞 |
MX2015004171A (es) | 2012-10-02 | 2015-10-22 | Glaxosmithkline Biolog Sa | Conjugados de sacaridos no lineales. |
KR20150073943A (ko) | 2012-10-03 | 2015-07-01 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
PL2912186T3 (pl) | 2012-10-24 | 2021-06-14 | Platelet Targeted Therapeutics Llc | Leczenie ukierunkowane na płytki krwi |
WO2014074785A1 (en) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
US9987344B2 (en) | 2012-11-30 | 2018-06-05 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
DK2928489T3 (en) | 2012-12-05 | 2019-04-23 | Glaxosmithkline Biologicals Sa | IMMUNOGENE COMPOSITION |
UY34506A (es) | 2012-12-10 | 2014-06-30 | Fernando Amaury Ferreira Chiesa | Adyuvante de vacunación, preparación y vacunas que lo contienen |
US10017543B2 (en) | 2013-03-13 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
EP2970409A2 (en) | 2013-03-15 | 2016-01-20 | Bioven 3 Limited | Self-assembling synthetic proteins |
BE1022174B1 (fr) | 2013-03-15 | 2016-02-24 | Glaxosmithkline Biologicals S.A. | Vaccin |
ES2728865T3 (es) | 2013-03-28 | 2019-10-29 | Infectious Disease Res Inst | Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis |
BR112015025709A2 (pt) | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
BR112015032388A8 (pt) | 2013-06-26 | 2020-01-14 | Univ North Carolina Chapel Hill | glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições |
EP3777882A1 (en) | 2013-07-30 | 2021-02-17 | BioNTech SE | Tumor antigens for determining cancer therapy |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
CN105555304A (zh) | 2013-08-05 | 2016-05-04 | 葛兰素史密丝克莱恩生物有限公司 | 联合免疫原性组合物 |
WO2015063611A2 (en) | 2013-11-01 | 2015-05-07 | University Of Oslo | Albumin variants and uses thereof |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
EP3068426B1 (en) | 2013-11-13 | 2020-02-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
DK3069138T3 (en) | 2013-11-15 | 2019-04-08 | Univ Oslo Hf | CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF |
WO2015077434A2 (en) | 2013-11-20 | 2015-05-28 | La Jolla Institute For Allergy And Immunology | Pan pollen immunogens and methods and uses for immune response modulation |
WO2015077442A2 (en) | 2013-11-20 | 2015-05-28 | La Jolla Institute For Allergy And Immunology | Grass pollen immunogens and methods and uses for immune response modulation |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
DK3107568T3 (da) | 2014-02-20 | 2024-06-03 | Vaxart Inc | Formuleringer til indgivelse til tyndtarmen |
TW201620927A (zh) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Uspa2蛋白質構築體及其用途 |
WO2015131053A1 (en) | 2014-02-28 | 2015-09-03 | Alk-Abelló A/S | Polypeptides derived from phl p and methods and uses thereof for immune response modulation |
CN107124869B (zh) * | 2014-03-25 | 2022-04-01 | 美国政府陆军部 | 包含含有单磷酰脂质a(mpla)的脂质体组合物和皂苷的无毒佐剂制剂 |
JP6894237B2 (ja) | 2014-03-26 | 2021-06-30 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 変異体ブドウ球菌抗原 |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
CN106536544B (zh) | 2014-06-25 | 2020-04-07 | 葛兰素史密丝克莱恩生物有限公司 | 艰难梭菌免疫原性组合物 |
TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
CN106715458A (zh) | 2014-07-18 | 2017-05-24 | 华盛顿大学 | 癌症疫苗组合物及其使用方法 |
WO2016012385A1 (en) | 2014-07-21 | 2016-01-28 | Sanofi Pasteur | Vaccine composition comprising ipv and cyclodextrins |
EP4112076A1 (en) | 2014-10-10 | 2023-01-04 | The Regents of The University of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
AU2015338859A1 (en) | 2014-11-02 | 2017-06-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
MX2017010698A (es) | 2015-02-20 | 2018-04-30 | Univ Texas | Metodos y composiciones para chlamydia atenuada como vacuna y vector. |
CA2977493C (en) | 2015-03-03 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Display platform from bacterial spore coat proteins |
EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
JP2018511655A (ja) | 2015-03-20 | 2018-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物 |
EP3273989B1 (en) | 2015-03-26 | 2023-12-27 | Gpn Vaccines Pty Ltd | Streptococcal vaccine |
CA2986961C (en) | 2015-05-26 | 2023-07-25 | Ohio State Innovation Foundation | Nanoparticle based vaccine strategy against swine influenza virus |
CN118045170A (zh) | 2015-06-12 | 2024-05-17 | 瓦克萨特公司 | 用于rsv和诺如病毒抗原的小肠递送的制剂 |
EP3138579A1 (en) | 2015-09-05 | 2017-03-08 | Biomay Ag | Fusion protein for use in the treatment of a hepatitis b virus infection |
CA3002323A1 (en) * | 2015-10-19 | 2017-04-27 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
KR20180077180A (ko) | 2015-11-06 | 2018-07-06 | 아쥬반스 테크놀로지스 인코포레이티드 | 트리테르펜 사포닌 유사체 |
GB201522132D0 (en) * | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Vaccine |
WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
GB201603625D0 (en) | 2016-03-02 | 2016-04-13 | Glaxosmithkline Biolog Sa | Novel influenza antigens |
WO2017156461A2 (en) | 2016-03-10 | 2017-09-14 | Aperisys, Inc. | Antigen-binding fusion proteins with modified hsp70 domains |
US11319383B2 (en) | 2016-03-14 | 2022-05-03 | Universitetet | Oslo | Engineered immunoglobulins with altered FcRn binding |
WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
WO2017167768A1 (en) | 2016-03-28 | 2017-10-05 | Glaxosmithkline Biologicals S.A. | Novel vaccine composition |
BR112018069468A2 (pt) | 2016-03-28 | 2019-07-30 | Toray Industries | agente indutor da imunidade, métodos para preparar uma célula apresentadora de antígeno, para preparar uma célula t citotóxica e para induzir a imunidade |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
CA3024313A1 (en) | 2016-05-21 | 2017-11-30 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
EP3471761A2 (en) | 2016-06-21 | 2019-04-24 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
PT3488443T (pt) | 2016-07-20 | 2021-09-24 | BioNTech SE | Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada |
US11498956B2 (en) | 2016-08-23 | 2022-11-15 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain(CD74) |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
US11801290B2 (en) | 2016-09-16 | 2023-10-31 | Access To Advanced Health Institute | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
EP3295956A1 (en) | 2016-09-20 | 2018-03-21 | Biomay Ag | Polypeptide construct comprising fragments of allergens |
EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
WO2018077385A1 (en) | 2016-10-25 | 2018-05-03 | Biontech Rna Pharmaceuticals Gmbh | Dose determination for immunotherapeutic agents |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
US11167022B2 (en) | 2017-03-31 | 2021-11-09 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
CN118085055A (zh) | 2017-04-19 | 2024-05-28 | 生物医学研究所 | 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽 |
KR102706661B1 (ko) * | 2017-04-25 | 2024-09-12 | 아쥬반스 테크놀로지스 인코포레이티드 | 트리테르펜 사포닌 유사체 |
WO2018198085A1 (en) | 2017-04-28 | 2018-11-01 | Glaxosmithkline Biologicals Sa | Vaccination |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
US12016919B2 (en) * | 2017-05-30 | 2024-06-25 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
CN107375921B (zh) * | 2017-06-12 | 2019-10-29 | 商丘美兰生物工程有限公司 | 一种甘草皂苷脂质体免疫佐剂及其制备方法 |
EP3638301A1 (en) | 2017-06-16 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Method of treatment |
AU2018304957A1 (en) | 2017-07-18 | 2020-02-13 | In3Bio Ltd | Synthetic proteins and therapeutic uses thereof |
WO2019034575A1 (en) | 2017-08-14 | 2019-02-21 | Glaxosmithkline Biologicals Sa | METHODS OF AMPLIFYING IMMUNE RESPONSES |
WO2019035963A1 (en) | 2017-08-16 | 2019-02-21 | Ohio State Innovation Foundation | NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA |
EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
JP2020533338A (ja) | 2017-09-07 | 2020-11-19 | ユニバーシティ オブ オスロUniversity of Oslo | ワクチン分子 |
WO2019051149A1 (en) | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE |
US11566050B2 (en) | 2017-10-18 | 2023-01-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus vaccines and diagnostics |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
CN111918666A (zh) | 2018-02-02 | 2020-11-10 | Sl瓦西基因公司 | 一种新型疫苗佐剂 |
CA3093509A1 (en) | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
EP3569612A1 (en) | 2018-05-18 | 2019-11-20 | Biomay Ag | Treatment and prevention of house dust mite allergies |
EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
US20210283238A1 (en) | 2018-08-07 | 2021-09-16 | Glaxosmithkline Biologicals Sa | Novel processes and vaccines |
CN112912097A (zh) | 2018-08-23 | 2021-06-04 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性蛋白和组合物 |
CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
EP3849521A1 (en) | 2018-09-14 | 2021-07-21 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
EP3890775A1 (en) | 2018-12-06 | 2021-10-13 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
US11419932B2 (en) | 2019-01-24 | 2022-08-23 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
GB201901608D0 (en) | 2019-02-06 | 2019-03-27 | Vib Vzw | Vaccine adjuvant conjugates |
CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
AU2020283768A1 (en) | 2019-05-25 | 2021-12-23 | Access To Advanced Health Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
JP2022539067A (ja) | 2019-06-25 | 2022-09-07 | イン3バイオ・リミテッド | 安定化キメラ合成タンパク質及びその治療的使用 |
KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
US20230066762A1 (en) | 2019-08-05 | 2023-03-02 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
EP3799884A1 (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
MX2022004061A (es) | 2019-10-02 | 2022-07-19 | Janssen Vaccines & Prevention Bv | Peptidos de estafilococo y metodos de uso. |
WO2021097347A1 (en) | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
WO2021122551A1 (en) | 2019-12-19 | 2021-06-24 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
KR20220128372A (ko) | 2020-01-16 | 2022-09-20 | 얀센 파마슈티칼즈, 인코포레이티드 | Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도 |
JP2023514825A (ja) | 2020-02-26 | 2023-04-11 | ヴェルシテック リミテッド | コロナウイルス感染症に対するpd-1ベースのワクチン |
EP4161570A1 (en) | 2020-06-05 | 2023-04-12 | GlaxoSmithKline Biologicals S.A. | Modified betacoronavirus spike proteins |
EP4188427A1 (en) | 2020-08-03 | 2023-06-07 | GlaxoSmithKline Biologicals S.A. | Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof |
US11225508B1 (en) | 2020-09-23 | 2022-01-18 | The University Of North Carolina At Chapel Hill | Mouse-adapted SARS-CoV-2 viruses and methods of use thereof |
CN113980140B (zh) | 2020-10-23 | 2024-06-25 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 融合蛋白及其应用 |
EP4237085A1 (en) | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
KR20230117166A (ko) | 2020-12-02 | 2023-08-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 공여자 가닥 보완된 FimH |
CA3207841A1 (en) | 2021-01-12 | 2022-07-21 | Janssen Pharmaceuticals, Inc | Fimh mutants, compositions therewith and use thereof |
EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
WO2022175423A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and methods |
EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
WO2022207645A1 (en) | 2021-03-30 | 2022-10-06 | Viravaxx AG | Sars-cov-2 subunit vaccine |
US20240156935A1 (en) | 2021-03-31 | 2024-05-16 | Vib Vzw | Vaccine Compositions for Trypanosomatids |
TW202304504A (zh) | 2021-04-01 | 2023-02-01 | 美商詹森藥物公司 | 大腸桿菌o18生物軛合物之生產 |
EP4362974A1 (en) | 2021-06-28 | 2024-05-08 | GlaxoSmithKline Biologicals S.A. | Novel influenza antigens |
WO2023046898A1 (en) | 2021-09-23 | 2023-03-30 | Viravaxx AG | Hbv vaccine inducing pres-specific neutralizing antibodies |
WO2023079528A1 (en) | 2021-11-05 | 2023-05-11 | King Abdullah University Of Science And Technology | Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses |
WO2023079529A1 (en) | 2021-11-05 | 2023-05-11 | King Abdullah University Of Science And Technology | Re-focusing protein booster immunization compositions and methods of use thereof |
EP4448548A1 (en) | 2021-12-13 | 2024-10-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Bacteriophage lambda-vaccine system |
WO2023114570A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
WO2023154960A1 (en) | 2022-02-14 | 2023-08-17 | University Of Georgia Research Foundation, Inc. | Pan-pneumovirus vaccine compositions and methods of use thereof |
WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
WO2024130009A1 (en) | 2022-12-14 | 2024-06-20 | Yale University | Compositions and methods of use thereof for the treatment of virally driven cancers |
WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
GB202219228D0 (en) | 2022-12-20 | 2023-02-01 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202303250D0 (en) | 2023-03-06 | 2023-04-19 | King S College London | Method and compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE69027112T2 (de) * | 1989-01-23 | 1997-01-09 | Auspharm International Ltd 4Th | Impfstoffzusammensetzung |
GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
NZ253137A (en) * | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
CA2156525A1 (en) * | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
PL178578B1 (pl) * | 1993-03-23 | 2000-05-31 | Smithkline Beecham Biolog | Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania |
ES2150493T5 (es) * | 1993-05-25 | 2004-07-01 | Wyeth Holdings Corporation | Adyuvantes para vacunas contra el virus sincitico respiratorio. |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
GB9718901D0 (en) † | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
-
1996
- 1996-01-04 UA UA97105147A patent/UA56132C2/uk unknown
- 1996-04-01 EP EP19980201600 patent/EP0884056A1/en not_active Ceased
- 1996-04-01 RO RO97-01969A patent/RO119068B1/ro unknown
- 1996-04-01 EP EP19990201323 patent/EP0955059B1/en not_active Expired - Lifetime
- 1996-04-01 DE DE1996605296 patent/DE69605296T3/de not_active Expired - Lifetime
- 1996-04-01 SI SI9630759T patent/SI0955059T1/sl unknown
- 1996-04-01 DE DE1996637254 patent/DE69637254T2/de not_active Expired - Lifetime
- 1996-04-01 AP APAP/P/1997/001123A patent/AP771A/en active
- 1996-04-01 PT PT99201323T patent/PT955059E/pt unknown
- 1996-04-01 SK SK1442-97A patent/SK282017B6/sk not_active IP Right Cessation
- 1996-04-01 CN CNB021529795A patent/CN1248737C/zh not_active Expired - Lifetime
- 1996-04-01 CA CA 2217178 patent/CA2217178C/en not_active Expired - Lifetime
- 1996-04-01 EA EA199700272A patent/EA000839B1/ru not_active IP Right Cessation
- 1996-04-01 AT AT99201323T patent/ATE373487T1/de active
- 1996-04-01 PL PL96322968A patent/PL184061B1/pl unknown
- 1996-04-01 KR KR1019970707527A patent/KR100463372B1/ko not_active IP Right Cessation
- 1996-04-01 CN CNB021529787A patent/CN1289065C/zh not_active Expired - Lifetime
- 1996-04-01 EP EP96910019A patent/EP0822831B2/en not_active Expired - Lifetime
- 1996-04-01 TR TR97/01252T patent/TR199701252T1/xx unknown
- 1996-04-01 AU AU53345/96A patent/AU693022B2/en not_active Expired
- 1996-04-01 WO PCT/EP1996/001464 patent/WO1996033739A1/en active IP Right Grant
- 1996-04-01 DK DK99201323T patent/DK0955059T3/da active
- 1996-04-01 AT AT96910019T patent/ATE186842T1/de active
- 1996-04-01 BR BR9608199A patent/BR9608199B1/pt active IP Right Grant
- 1996-04-01 SI SI9630076T patent/SI0822831T2/sl unknown
- 1996-04-01 NZ NZ30536596A patent/NZ305365A/xx not_active IP Right Cessation
- 1996-04-01 ES ES99201323T patent/ES2293708T3/es not_active Expired - Lifetime
- 1996-04-01 ES ES96910019T patent/ES2140076T5/es not_active Expired - Lifetime
- 1996-04-01 CN CN96193443A patent/CN1111071C/zh not_active Expired - Lifetime
- 1996-04-01 CZ CZ0337997A patent/CZ296216B6/cs not_active IP Right Cessation
- 1996-04-01 HU HU9801560A patent/HU227944B1/hu unknown
- 1996-04-01 DK DK96910019T patent/DK0822831T4/da active
- 1996-04-01 JP JP53212296A patent/JP3901731B2/ja not_active Expired - Lifetime
- 1996-04-23 AR AR33625396A patent/AR001686A1/es unknown
- 1996-04-23 TW TW85104841A patent/TW515715B/zh not_active IP Right Cessation
- 1996-04-23 IL IL11800496A patent/IL118004A/xx not_active IP Right Cessation
- 1996-04-23 MA MA24212A patent/MA23850A1/fr unknown
- 1996-04-23 MY MYPI96001550A patent/MY134811A/en unknown
- 1996-04-24 DZ DZ960068A patent/DZ2026A1/fr active
- 1996-09-16 SA SA96170297A patent/SA96170297B1/ar unknown
-
1997
- 1997-10-21 NO NO19974859A patent/NO322190B1/no not_active IP Right Cessation
- 1997-10-24 OA OA70114A patent/OA10629A/en unknown
- 1997-10-24 BG BG101995A patent/BG63491B1/bg unknown
-
1998
- 1998-06-03 AU AU69873/98A patent/AU699213B2/en not_active Expired
- 1998-08-11 HK HK98109853A patent/HK1009086A1/xx not_active IP Right Cessation
-
1999
- 1999-11-25 GR GR990402990T patent/GR3031912T3/el unknown
-
2000
- 2000-04-28 HK HK00102603A patent/HK1025244A1/xx not_active IP Right Cessation
-
2008
- 2008-01-16 CY CY0800001A patent/CY2588B2/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW515715B (en) | Vaccine compositions having immunologically active QS21 | |
US6846489B1 (en) | Vaccines containing a saponin and a sterol | |
AU714930B2 (en) | Vaccines | |
JP3755890B2 (ja) | アジュバント含有ワクチン組成物 | |
ES2285036T3 (es) | Coadyuvantes basados en una emulsion y mpl para vacunas. | |
US20110243971A1 (en) | Vaccines | |
AU687494C (en) | Vaccines | |
MXPA97008226A (es) | Vacunas que contienen una saponina y un esterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |